56 research outputs found
Endothelial progenitor cells: Potential novel therapeutics for ischaemic stroke
Stroke is classified into two main groups depending on its aetiology; ischaemic stroke and haemorrhagic stroke which successively develop from the occlusion or rupture of an artery leading to the brain. Despite being the leading cause of human cerebral damage, there is currently no medical therapy for haemorrhagic stroke and thrombolysis with recombinant tissue plasminogen activator remains the only approved pharmacotherapy for ischaemic stroke. However, due to its short therapeutic window (first 4.5 h of stroke onset) and increased risk of haemorrhage beyond this point, globally each year less than 1% of patients receive this therapy. Since, endothelial dysfunction, associated with inflammation and vascular permeability, remains the key early event in the pathogenesis of stroke, endogenous element(s) capable of countering this defect may help maintain vascular homeostasis and explain the overt differences observed in patients’ functional outcome. Accumulating evidence indicate that bone marrow-derived endothelial progenitor cells (EPCs) equipped with an inherent capacity to repair endothelial damage and differentiate into few other cell lines represent one such element. Indeed, EPC-based cell therapy, backed by rigorous preclinical, translational and early proof-of-concept, safety and feasibility clinical studies, is now considered as an important novel therapeutic approach. However, several questions relating to optimal cell dosage, delivery route and immediate and sufficient availability of cells remain to be addressed before its efficacious translation to clinical practice. In this context, ex vivo expansion of EPCs leading to an abundant generation of functional outgrowth endothelial cells offers a great opportunity to address these issues and create a novel off-the-shelf type of therapeutic product
Vitamins Reverse Endothelial Dysfunction Through Regulation of eNOS and NAD(P)H Oxidase Activities
Antioxidant vitamins C and E have protective properties in genetic hypertension associated with enhanced
oxidative stress. This study investigated whether vitamins C and/or E modulate vascular function by regulating
enzymatic activities of endothelial nitric oxide synthase (eNOS) and NAD(P)H oxidase using thoracic aortas of 20- to
22-week-old male spontaneously hypertensive rats (SHR) and their matched normotensive counterparts, Wistar-Kyoto
rats (WKY). SHR aortas had impaired relaxant responses to acetylcholine but not to sodium nitroprusside, despite an
2-fold increase in eNOS activity and NO release. The levels of superoxide anion (O2
), a potent NO scavenger, and
NAD(P)H oxidase activity were also 2-fold higher in SHR aortas. Mechanical but not pharmacological inactivation of
endothelium (by rubbing and 100 mol/L L-NAME, respectively) significantly abrogated O2
in both strains.
Treatments of SHR aortas with NAD(P)H oxidase inhibitors, namely diphenyleneiodinium and apocynin, significantly
diminished O2
production. The incubation of SHR aortas with different concentrations of vitamin C (10 to 100 mol/L)
and specifically with high concentrations of vitamin E (100 mol/L) improved endothelial function, reduced superoxide
production as well as NAD(P)H oxidase activity, and increased eNOS activity and NO generation in SHR aortas to the
levels observed in vitamin C- and E-treated WKY aortas. Our results reveal endothelial NAD(P)H oxidase as the major
source of vascular O2
in SHR and also show that vitamins C and E are critical in normalizing genetic endothelial
dysfunction through regulation of eNOS and NAD(P)H oxidase activities
Prognostic, diagnostic and therapeutic potential of endothelial progenitor cells for patients with ischaemic stroke: Hype or Hope
Ischaemic stroke is a debilitating disease with immense personal, societal and economic impact. Thrombolysis with recombinant tissue plasminogen activator remains the only approved pharmacotherapy for this disease. As each year less than 1% of eligible patients receive this therapy worldwide, efficacious new therapeutics are desperately needed. Emerging evidence suggest endothelial progenitor cells (EPCs), capable of repairing damaged vasculature, as one such therapeutics. However, questions regarding their optimal dose, delivery route and in vivo survivability remain largely unanswered. Outgrowth endothelial cells, generated in large numbers by ex vivo expansion of EPCs, enable effective assessment of these issues and may eventually serve as off-the-shelf therapeutics. Correlations between circulating EPC levels and stroke outcome imply that EPCs may also serve as clinical biomarkers for stroke. This viewpoint briefly evaluates the current evidence, pinpoints the gaps in the literature and proposes new directions for research
Molecular Characterization and Localization of the NAD(P)H Oxidase Components gp91-phox and p22-phox in Endothelial Cells
The production of reactive oxygen species (ROS) within endothelial cells may have several effects, including
alterations in the activity of paracrine factors, gene expression, apoptosis, and cellular injury. Recent studies indicate that
a phagocyte-type NAD(P)H oxidase is a major source of endothelial ROS. In contrast to the high-output phagocytic
oxidase, the endothelial enzyme has much lower biochemical activity and a different substrate specificity
(NADH.NADPH). In the present study, we (1) cloned and characterized the cDNA and predicted amino acid structures
of the 2 major subunits of rat coronary microvascular endothelial cell NAD(P)H oxidase, gp91-phox and p22-phox;
(2) undertook a detailed comparison with phagocytic NADPH oxidase sequences; and (3) studied the subcellular
location of these subunits in endothelial cells. Although these studies revealed an overall high degree of homology
(.90%) between the endothelial and phagocytic oxidase subunits, the endothelial gp91-phox sequence has potentially
important differences in a putative NADPH-binding domain and in putative glycosylation sites. In addition, the
subcellular location of the endothelial gp91-phox and p22-phox subunits is significantly different from that reported for
the neutrophil oxidase, in that they are predominantly intracellular and collocated in the vicinity of the endoplasmic
reticulum. This first detailed characterization of gp91-phox and p22-phox structure and location in endothelial cells
provides new data that may account, in part, for the differences in function between the phagocytic and endothelial
NAD(P)H oxidases
Hyperglycaemia promotes human brain microvascular endothelial cell apoptosis via induction of protein kinase C-βI and prooxidant enzyme NADPH oxidase
Blood–brain barrier disruption represents a key feature in hyperglycaemia-aggravated cerebral damage after an ischaemic stroke. Although the underlying mechanisms remain largely unknown, activation of protein kinase C (PKC) is thought to play a critical role. This study examined whether apoptosis of human brain microvascular endothelial cells (HBMEC) might contribute to hyperglycaemia-evoked barrier damage and assessed the specific role of PKC in this phenomenon. Treatments with hyperglycaemia (25 mM) or phorbol myristate acetate (PMA, a protein kinase C activator, 100 nM) significantly increased NADPH oxidase activity, O(2)(•-) generation, proapoptotic protein Bax expression, TUNEL-positive staining and caspase-3/7 activities. Pharmacological inhibition of NADPH oxidase, PKC-a, PKC-ß or PKC-ß(I) via their specific inhibitors and neutralisation of O(2)(•-) by a cell-permeable superoxide dismutase mimetic, MnTBAP normalised all the aforementioned increases induced by hyperglycaemia. Suppression of these PKC isoforms also negated the stimulatory effects of hyperglycaemia on the protein expression of NADPH oxidase membrane-bound components, Nox2 and p22-phox which determine the overall enzymatic activity. Silencing of PKC-ß(I) gene through use of specific siRNAs abolished the effects of both hyperglycaemia and PMA on endothelial cell NADPH oxidase activity, O(2)(•-) production and apoptosis and consequently improved the integrity and function of an in vitro model of human cerebral barrier comprising HBMEC, astrocytes and pericytes. Hyperglycaemia-mediated apoptosis of HBMEC contributes to cerebral barrier dysfunction and is modulated by sequential activations of PKC-ß(I) and NADPH oxidase
Internal mammary artery smooth muscle cells resist migration and possess high antioxidant capacity
Objective- This study investigated whether differences exist in atherogen-induced migratory behaviors and basal antioxidant enzyme capacity of vascular smooth muscle cells (VSMC)
from human coronary (CA) and internal mammary (IMA) arteries.
Methods- Migration experiments were performed using the Dunn chemotaxis chamber. The prooxidant [NAD(P)H oxidase] and antioxidant [NOS, superoxide dismutase, catalase and
glutathione peroxidase] enzyme activities were determined by specific assays.
Results- Chemotaxis experiments revealed that while both sets of VSMC migrated towards
platelet-derived growth factor-BB (1-50 ng/ml) and angiotensin II (1-50 nM), neither
oxidized-LDL (ox-LDL, 25-100 ïÂ�ÂÂg/ml) nor native LDL (100 ïÂ�ÂÂg/ml) affected chemotaxis in
IMA VSMC. However, high dose ox-LDL produced significant chemotaxis in CA VSMC
that was inhibited by pravastatin (100 nM), mevastatin (10 nM), losartan (10 nM), enalapril
(1 ïÂ�ÂÂM), and MnTBAP (a free radical scavenger, 50ïÂ� ïÂ�ÂÂM). Microinjection experiments with
isoprenoids i.e. geranylgeranylpyrophosphate (GGPP) and farnesylpyrophosphate (FPP)
showed distinct involvement of small GTPases in atherogen-induced VSMC migration.
Significant increases in antioxidant enzyme activities and nitrite production along with
marked decreases in NAD(P)H oxidase activity and O2
.- levels were determined in IMA
versus CA VSMC.
Conclusions- Enhanced intrinsic antioxidant capacity may confer on IMA VSMC resistance
to migration against atherogenic agents. Drugs that regulate ox-LDL or angiotensin II levels
also exert antimigratory effects
Role of gender, smoking profile, hypertension, and diabetes on saphenous vein and internal mammary artery endothelial relaxation in patients with coronary artery bypass grafting
The aim of this study was to investigate if there was a link between the relaxant responses in saphenous vein (SV) and internal mammary artery (IMA) segments obtained from patients undergoing coronary artery bypass grafting and the patients' cardiovascular risk factors. Endothelium-(in)dependent relaxations were assessed by isometric tension studies. Endothelium-dependent relaxant responses were greater in IMA than SV and gender, smoking profile and history of hypertension but not diabetes appeared to have an influence on these responses. Endothelium-dependent relaxant responses in both IMA and SV were greater in males than females and relaxant responses in IMA segments were attenuated in smokers, whereas the opposite effect was noted in SV segments. Endothelium-dependent relaxant responses in SV were lower in patients with hypertension. Endothelium-independent relaxant responses were greater in IMA than SV. Endothelium-independent responses were greater in male patients' SV segments, but gender played no role in IMA segments. Diabetes had no effect on endothelium-independent responses in IMA, but SV segments from diabetic patients had greater responses. Neither conduit's endothelium-independent response was affected by hypertensive status. The relationship between risk factor status and endothelial responses is multifactorial, with gender, hypertension, diabetes and smoking status all contributing
Urokinase Plasminogen Activator: A Potential Thrombolytic Agent for Ischaemic Stroke
Stroke continues to be one of the leading causes of mortality and morbidity worldwide. Restoration of cerebral blood flow by recombinant plasminogen activator (rtPA) with or without mechanical thrombectomy is considered the most effective therapy for rescuing brain tissue from ischaemic damage, but this requires advanced facilities and highly skilled professionals, entailing high costs, thus in resource-limited contexts urokinase plasminogen activator (uPA) is commonly used as an alternative. This literature review summarises the existing studies relating to the potential clinical application of uPA in ischaemic stroke patients. In translational studies of ischaemic stroke, uPA has been shown to promote nerve regeneration and reduce infarct volume and neurological deficits. Clinical trials employing uPA as a thrombolytic agent have replicated these favourable outcomes and reported consistent increases in recanalisation, functional improvement and cerebral haemorrhage rates, similar to those observed with rtPA. Single-chain zymogen pro-urokinase (pro-uPA) and rtPA appear to be complementary and synergistic in their action, suggesting that their co-administration may improve the efficacy of thrombolysis without affecting the overall risk of haemorrhage. Large clinical trials examining the efficacy of uPA or the combination of pro-uPA and rtPA are desperately required to unravel whether either therapeutic approach may be a safe first-line treatment option for patients with ischaemic stroke. In light of the existing limited data, thrombolysis with uPA appears to be a potential alternative to rtPA-mediated reperfusive treatment due to its beneficial effects on the promotion of revascularisation and nerve regeneration
- …